Irina Rebin

Irina is member of the Practice Area Patents Technology & Life Sciences and the Life Sciences & Healthcare Industry Group. Her practice includes advising pharmaceutical, medical device, and biotechnology companies and investors on all regulatory matters throughout the entire life cycle of medicinal products, medical devices, and IVDs: from preclinical research and clinical trials, manufacturing, and market access to distribution (including post-market surveillance).

She also provides legal advice on genetic engineering, food (including food supplements), and cosmetics. Irina complements this practice focus by drafting and negotiating corresponding industry-specific agreements (including research and development agreements, license agreements, clinical trial agreements, contract/manufacturing and distribution agreements (including quality agreements)) and by advising on (cross-border) transactions in the healthcare sector.

CV

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

职业发展

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

教育

2019 Second state examination, Munich

2014 – 2017 Doctoral studies at Ludwig Maximilians University Munich

2014 - 2015 Doctoral studies at Georg August University Göttingen

Publications

§§ 40-42e AMG in: Rehmann, AMG, 6. Aufl. [in Bearb./vor. Anfang 2026] § 15 Entwicklung des Arzneimittelprüfrechts

§ 16 Grundlagen klinischer Arzneimittelprüfungen

§ 17 Zentrale Voraussetzungen klinischer Prüfungen im Überblick in: Spickhoff/Handorn: Handbuch Medizinisches Forschungsrecht, C. H. Beck, München, 2023

§ 2 ProdHaftG im Beck-Online-Großkommentar (seit 2015)

语言

奖励

JUVE Awards 2023

Featured

最新新闻和观点

View Irina's insights

点击此处了解更多

酒店与休闲

Research and innovation as a competitive advantage – Legal framework for Life Sciences made in Europe

2026年1月27日

作者 Irina Rebin

酒店与休闲

Life Sciences Made in Europe – The European Commission’s Life Sciences Strategy 2030

2026年1月27日

In-depth analysis

作者 Irina Rebin

点击此处了解更多

酒店与休闲

Adoption of Commission Implementing Regulation (EU) 2025/2086: New Rules on the Joint Clinical Assessment of Medical Devices and In Vitro Diagnostic Medical Devices

2026年1月23日

Briefing

作者 Irina Rebin 以及 Daniel Dietrich

点击此处了解更多

Irina Rebin

JUVE Awards 2023

专长

执业领域和服务团队

行业

CV

职业发展

教育

Publications

语言

奖励

JUVE Awards 2023

最新新闻和观点

Research and innovation as a competitive advantage – Legal framework for Life Sciences made in Europe

Irina Rebin

JUVE Awards 2023

专长

执业领域和服务团队

行业

CV

职业发展

教育

Publications

语言

奖励

JUVE Awards 2023

最新新闻和观点

Research and innovation as a competitive advantage – Legal framework for Life Sciences made in Europe

Related news & insights

Flensburg Regional Court: no entitlement to claim damages based on the market price

Arbitration nation

More Than Share and Asset Deals: Innovative Transaction Structures for MedTech Companies

Advising on Tropic Biosciences' US$105 million Series C financing

2026 Lexology Panoramic Guide on Distribution & Agency in Germany

Supply Chain Resilience: The ability to act in uncertain times: using the Hormuz blockade as an example

The UK's economic crime revolution: navigating the new era of corporate criminal liability

Proportionality considerations in proceedings before the UPC

What are the litigation trends in 2026?

Not so public opinion: abolition of juries

相关人员

与我会面：

Product Liability meets Mass Claims